Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Recruiting

Phase 2

VX-407Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Sponsor:

Vertex Pharmaceuticals Incorporated

Code:

NCT07161037

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Eligibility Criteria

Sex: All

Age: 18 - 65

Healthy Volunteers: Not accepted

Interventions

VX-407

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-26. This information was provided to ClinicalTrials.gov by Vertex Pharmaceuticals Incorporated on 2026-05-13.